Immunome, Inc.

IMNM Healthcare Biotechnology

Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.

Revenue
+69.8%
EPS
−30.0%
Free cash flow
−27.0%

Quarter to June 2026, against a year earlier

18.58 0.67 +3.74%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−7.6×
Dividend yield
—
F-score
4/9
Altman Z
21.57
Beneish M
n/a
Dividend safety
n/a

Immunome, Inc. (IMNM) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Immunome, Inc. (IMNM) trades at a EV/FCF of −7.0×. Over the past ten years it has ranged from −48.2× (March 2024) to 33.0× (June 2023); the current reading is higher than 35% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 −6.1× —
FY2024 −3.4× —
FY2023 −9.6× —

Quarterly newest first

Period EV/FCF Change
Jun 2025 −2.9× —
Mar 2025 −1.3× —
Dec 2024 −3.4× —
Sep 2024 −6.9× —
6 more quarters

Against its own ten years

Low −48.2× High 33.0×
Ten-year median −3.7×
Current reading's percentile 35

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on IMNM